Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

ENV-294 til moderat til svær astma: Et 12-ugers studie hos voksne

22. september 2026 opdateret af: Enveda Therapeutics

En fase 2, randomiseret, dobbeltblind, placebo-kontrolleret, parallel-gruppe, 12-ugers undersøgelse for at evaluere effektiviteten, sikkerheden og farmakokinetikken af ENV-294 hos voksne deltagere med moderat til svær astma

This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and potential efficacy of ENV-294 in adults with moderate to severe asthma who are receiving background treatment with inhaled corticosteroids (ICS) and long-acting beta₂-agonists (LABA).

Participants will take oral ENV-294 or placebo once daily for 12 weeks. The study includes a screening period of up to 28 days before randomization to confirm eligibility. Study visits and assessments will be conducted to monitor safety, measure drug levels in the blood, and evaluate effects on asthma control and lung function.

Studieoversigt

Status

Rekruttering

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

50

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35209
        • Rekruttering
        • Enveda Investigative Site
    • California
      • Los Angeles, California, Forenede Stater, 90025
        • Rekruttering
        • Enveda Investigative Site
      • San Jose, California, Forenede Stater, 95117
        • Rekruttering
        • Enveda Investigative Site
      • West Hills, California, Forenede Stater, 91307
        • Rekruttering
        • Enveda Investigative Site
    • Colorado
      • Colorado Springs, Colorado, Forenede Stater, 80907
        • Rekruttering
        • Enveda Investigative Site
    • Florida
      • Hialeah, Florida, Forenede Stater, 33012
        • Rekruttering
        • Enveda Investigative Site
      • Miami, Florida, Forenede Stater, 33135
        • Rekruttering
        • Enveda Investigative Site
    • Georgia
      • Albany, Georgia, Forenede Stater, 31707
        • Rekruttering
        • Enveda Investigative Site
    • Illinois
      • Maryville, Illinois, Forenede Stater, 62062
        • Rekruttering
        • Enveda Investigative Site
    • Kansas
      • Kansas City, Kansas, Forenede Stater, 66160
        • Rekruttering
        • Enveda Investigative Site
    • Kentucky
      • Owensboro, Kentucky, Forenede Stater, 42301
        • Rekruttering
        • Enveda Investigative Site
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02115
        • Rekruttering
        • Enveda Investigative Site
    • Michigan
      • Southfield, Michigan, Forenede Stater, 48075
        • Rekruttering
        • Enveda Investigative Site
    • Missouri
      • St Louis, Missouri, Forenede Stater, 63141
        • Rekruttering
        • Enveda Investigative Site
    • New York
      • The Bronx, New York, Forenede Stater, 10455
        • Rekruttering
        • Enveda Investigative Site
    • Oregon
      • Clackamas, Oregon, Forenede Stater, 97015
        • Rekruttering
        • Enveda Investigative Site
      • Medford, Oregon, Forenede Stater, 97504
        • Rekruttering
        • Enveda Investigative Site
    • South Carolina
      • North Charleston, South Carolina, Forenede Stater, 29406
        • Rekruttering
        • Enveda Investigative Site
    • Texas
      • McKinney, Texas, Forenede Stater, 75069
        • Rekruttering
        • Enveda Investigative Site
    • Wisconsin
      • Madison, Wisconsin, Forenede Stater, 53792
        • Rekruttering
        • Enveda Investigative Site

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 75 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Able to read, understand, and sign an informed consent form before any study procedures
  • Male or female adults aged 18 to 75 years with a physician diagnosis of moderate to severe asthma for at least 12 months
  • Receiving stable treatment with an inhaled corticosteroid (ICS) plus a long-acting beta₂-agonist (LABA) for at least 2 months before screening
  • Pre-bronchodilator FEV₁ between 50% and 80% of predicted normal at screening and baseline
  • Demonstrated bronchodilator reversibility
  • ACQ-5 score ≥1.25 to ≤3.0 at screening and baseline
  • History of at least one asthma exacerbation in the past 12 months requiring systemic corticosteroids or hospitalization/emergency care

Exclusion Criteria:

  • Recent moderate or severe asthma exacerbation (within 4 weeks before screening)
  • History of life-threatening asthma
  • Other significant pulmonary disease
  • Recent bronchial thermoplasty (within 2 years)
  • Uncontrolled current or recurrent concomitant illness
  • Recent use of biologic therapies for asthma (within 6 months or 5 half-lives)
  • Require immunosuppressive medications or frequent systemic corticosteroids
  • Current smokers or former smokers with significant smoking history
  • Uncontrolled hypertension
  • Significant hepatic impairment

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Firedobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: ENV-294 Treatment Arm

ENV-294 will be administered to those participants randomized to the treatment arm.

ENV-294 is an orally administered investigational drug supplied as tablets. Participants receive ENV-294 once daily by mouth for 12 weeks.

Placebo komparator: Placebo Arm

A placebo will be administered to those participants randomized to the placebo arm.

Matching oral tablet that does not contain active drug. Administered once daily by mouth for 12 weeks under the same conditions as the investigational product.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Incidence and Severity of Adverse Events
Tidsramme: From first dose through approximately 16 weeks

Number and percentage of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), and adverse events leading to discontinuation of study drug.

From first dose through approximately 16 weeks

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Loss of Asthma Control Events
Tidsramme: Baseline to Week 12

Number and percentage of participants experiencing a loss of asthma control (LOAC) event during the treatment period, defined according to protocol-specified criteria

Baseline to Week 12
Time to Loss of Asthma Control
Tidsramme: Baseline to Week 12

Time from the first dose of study drug to the first occurrence of a loss of asthma control (LOAC) event, as defined in the protocol.

Baseline to Week 12
To assess the efficacy of ENV-294 in participants with asthma
Tidsramme: Baseline to Week 12

Change from baseline in pre- and post-bronchodilator forced expiratory volume in 1 second (FEV₁), measured using standardized spirometry.

Baseline to Week 12
To assess the efficacy of ENV-294 in participants with asthma
Tidsramme: Baseline to Week 12

Change from Baseline in the Asthma Control Questionnaire (ACQ-5)

Baseline to Week 12
To assess the efficacy of ENV-294 in participants with asthma
Tidsramme: Baseline to Week 12

Change from Baseline in the Asthma Quality of Life Questionnaire (AQLQ)

Baseline to Week 12
Plasma concentration of ENV-294
Tidsramme: Baseline to Week 12

Plasma concentrations of ENV-294 will be measured at specified time points following oral administration of the investigational drug.

Baseline to Week 12

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Studieleder: Gurpreet Ahluwalia, PhD, Enveda Therapeutics, Inc.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

9. januar 2026

Primær færdiggørelse (Anslået)

1. december 2026

Studieafslutning (Anslået)

1. januar 2027

Datoer for studieregistrering

Først indsendt

10. december 2025

Først indsendt, der opfyldte QC-kriterier

23. december 2025

Først opslået (Faktiske)

24. december 2025

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

24. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

22. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

Individual participant data (IPD) will not be shared. The data include sensitive health information that cannot be fully de-identified under current privacy standards, and the sponsor does not plan to make IPD available outside the study team. Summary results and aggregate data will be shared publicly as required by regulation.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner